A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

Phase 2

Terminated

• Conditions: Primary Sjögren Syndrome
• Interventions: Drug: Placebo; Drug: GLPG3970

• Registration Number: NCT04700280
• Lead Sponsor: Galapagos NV

Brief Summary

This is a first exploration of GLPG3970 in participants with active primary Sjogren's Syndrome (pSS) to evaluate the efficacy, safety and tolerability and to determine its pharmacokinetics (PK) profile compared to placebo.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-01-06
• Study First Submitted QC: 2021-01-06
• Study First Posted: 2021-01-07
• Study Start: 2021-01-28
• Primary Completion: 2021-10-28
• Study Completion: 2021-12-27
• Status Verified: 2022-11
• Results First Submitted: 2022-11-08
• Results First Submitted QC: 2022-11-08
• Last Update Submitted: 2022-11-08
• Results First Posted: 2023-09-18
• Last Update Posted: 2023-09-18

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

1. Documented diagnosis of pSS for <10 years prior to screening AND defined by the classification criteria >=4 described by the American College of Rheumatology - European League Against Rheumatism (ACR-EULAR).

2. Participant has an ESSDAI score >=5 assessed on 7 domains: constitutional, lymphadenopathy, glandular, articular, cutaneous, hematological, and biological.

3. Participant has an ESSPRI score >=5.

4. Participant has stimulated whole salivary flow rate of >=0.1 milliliter per minute (mL/min).

5. Participant has positive serum titers of anti-Sjögren's-syndrome-related antigen A (anti-SS-A)/Ro and/or anti-SS-B/La antibodies.

6. Participants already on treatment should be on stable standard of care (SoC) for at least 4 weeks prior to first investigational product (IP) dosing.

   The following SoC medications are permitted:

   • Corticosteroids <=7.5 mg/day (prednisone or equivalent); AND/OR
   • Non-steroidal anti-inflammatory drugs (NSAIDs); AND/OR
   • One single antimalarial at a stable dose (hydroxychloroquine <=400 mg/day; quinacrine 100 mg/kg/day, or chloroquine <=250 mg/day); AND/OR
   • One single immunosuppressant at a stable dose (methotrexate [MTX] <=10 mg/week or azathioprine [AZA] <=2 mg/kg/day); AND/OR
   • One single cholinergic stimulant at a stable dose (e.g., pilocarpine, cevimeline).

7. Female participant of childbearing potential must have a negative highly sensitive (serum beta human chorionic gonadotropin or urine dipstick) pregnancy test.

8. Female participant of childbearing potential or male participant must agree to use highly effective contraception/preventive exposure measures.

Key

Read More

Exclusion Criteria

1. Secondary Sjögren's syndrome according to the ACR-EULAR (2016) classification.

2. History or presence of unstable condition not related to Sjögren's Syndrome that, in the opinion of the investigator, could constitute an unacceptable risk when taking the IP or interfere with the interpretation of data.

3. Participant has any active systemic infection within 2 weeks prior to first IP dosing, or poorly controlled chronic cardiac, pulmonary, or renal disease.

4. Participant has a known or suspected history of or a current immunosuppressive condition, or a history of opportunistic infections (e.g., human immunodeficiency virus [HIV] infection, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis).

5. Participant has a chronic hepatitis B virus (HBV) infection, as defined by persistent HBV surface antigen (HBsAg) positivity. Participant has hepatitis C virus (HCV) infection, as defined by positive HCV antibody at screening and detectable HCV viremia. Participants with positive HCV antibody must undergo reflex HCV ribonucleic acid (RNA) testing, and participants with HCV RNA positivity will be excluded. Participants with positive HCV antibody and negative HCV RNA are eligible.

6. Participant testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as detected at screening based on real time polymerase chain reaction (RT-PCR) or at baseline based on immunoglobulin M (IgM) immunoassay, or participants who have been in contact with SARS-CoV-2 infected individuals in the 2 weeks prior to first dosing of IP. Participants presenting any signs or symptoms of SARS-CoV-2 infection, as detected prior to first IP dosing following careful physical examination (e.g., cough, fever, headaches, fatigue, dyspnea, myalgia, anosmia, dysgeusia, anorexia, sore throat, etc). In addition, any other locally applicable standard diagnostic criteria may also apply to rule out SARS-CoV-2 infection.

7. Participant has taken any disallowed therapies:

   • Mycophenolate mofetil (MMF) within a week prior to screening.
   • Cyclosporine/Tacrolimus within a week prior to screening.
   • Cyclophosphamide within 6 months prior to screening.
   • Ocular medicines (e.g., topical cyclosporine, topical NSAIDs/ corticosteroids) for at least 4 weeks prior to screening, except for a sporadic use.
   • Biologics such as, but not limited to, rituximab, abatacept, and any other unapproved biologic within 6 months prior to screening.
   • Plasmapheresis within 12 weeks prior to screening.
   • Plasma exchange within 12 weeks prior to screening.
   • Intravenous immunoglobulin (IVIG) therapy within 24 weeks prior to screening.
   • Other prohibited medications within 2 weeks or 5 half-lives, whichever is longer, prior to first IP dosing.

8. Concurrent use of anticholinergic agents or any other medication known to cause dry mouth/dry eyes that, in the opinion of the investigator, are a contributing factor to the participant's dryness and/or use of anticholinergic agents not contributing to this dryness, if not stable at least 4 weeks prior to screening.

9. Participant has a history of tuberculosis (TB) diagnosis or evidence of active or latent infection with Mycobacterium tuberculosis.

10. Participant has a history of lymphoma or any malignancy within the past 5 years prior to screening with the exception of excised and curatively treated non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of cervix which is considered cured with minimal risk of recurrence.

11. Participant has severe organ manifestation or life-threatening condition, or has planned a surgery during the study.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Participants will receive placebo matched to GLPG3970 tablet, orally, once daily for 12 weeks.
GLPG3970	GLPG3970	Participants will receive GLPG3970 400 milligrams (mg) (2 \*200 mg tablet), orally, once daily for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) by Severity	From first dose of study drug up to 30 days after last dose of study drug (maximum duration=16 weeks)	An adverse event (AE) was any untoward medical occurrence in a participant administered study drug and which did not necessarily have a causal relationship with study drug. The severity of AEs was graded using the Common Terminology Criteria for Adverse Events (CTCAE) current version at the time of assessment. The maximum intensity of the AE were Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), or Grade 5 (fatal). A TEAE was any AE with an onset date on or after the first dose of GLPG3970 and no later than 30 days after last dose of GLPG3970, or any worsening of any AE on or after the GLPG3970 start date.
Change From Baseline in European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 12	Baseline, Week 12	The ESSDAI is a systemic disease activity index to assess 12 domains (organ systems: constitutional, lymphadenopathy and lymphoma, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, CNS, hematological, biological) in participants with pSS. Each of the domains was assessed for activity level (no, low, moderate, and high). Each domain score was obtained by multiplying the activity level with the domain weight, ranged from 1 to 6, and assigned a numerical score based on pre-determined weighting of each individual domain. The sum of all individual weighted domain scores was the overall score, ranged from 0 (best) to 123 (worst activity). A higher score indicated more disease activity. A clinically meaningful reduction from baseline (≥3 points) indicated the improvement of symptoms. Least squares (LS) mean was calculated using mixed models for repeated measures (MMRM).

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Weeks 4, 8, and 12	Baseline, Weeks 4, 8, and 12	The ESSPRI is a participant-reported questionnaire to assess subjective participant symptoms and includes 3 domains (dryness, pain, and fatigue). Each domain was scored on scale of 0-10 (0 = no symptom at all and 10 = worst symptom imaginable), and an overall score was calculated as the mean of the 3 individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10. A higher score indicates worst symptom. A clinically significant reduction from baseline of the ESSPRI score (at least one point or 15% of the baseline value) indicated the improvement of symptoms.
Change From Baseline in ESSDAI Score at Weeks 4, 8, and 12	Baseline, Weeks 4, 8, and 12	The ESSDAI is a systemic disease activity index to assess 12 domains (organ systems: constitutional, lymphadenopathy and lymphoma, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous system, CNS, hematological, biological) in participants with pSS. Each of the domains was assessed for activity level (no, low, moderate, and high). Each domain score was obtained by multiplying the activity level with the domain weight, ranged from 1 to 6, and assigned a numerical score based on pre-determined weighting of each individual domain. The sum of all individual weighted domain scores was the overall score, ranged from 0 (best) to 123 (worst activity). A higher score indicated more disease activity. A clinically meaningful reduction from baseline (≥3 points) indicated the improvement of symptoms. Results of Week 12 is presented in primary outcome measure 1.
Observed Pre-dose Plasma Concentration (Ctrough) of GLPG3970	Pre-dose (within 30 minutes prior to dosing) on Weeks 1, 4, 8, and 12	Plasma concentration of GLPG3970 observed at pre-dose in nanogram per milliliter (ng/mL), obtained directly from the observed concentration versus time data.

Trial Locations

Locations (10)

Debreceni Egyetem; 🇭🇺 Debrecen, Hungary

Szpital Uniwersytecki nr 2 im.dr J. Biziela; 🇵🇱 Bydgoszcz, Poland

NZOZ Centrum Medyczne Reuma Park; 🇵🇱 Warsaw, Poland

General Hospital of Athens Laiko; 🇬🇷 Athens, Greece

ETG Lublin; 🇵🇱 Lublin, Poland

Centrum Badan Klinicznych S.C.; 🇵🇱 Poznań, Poland

Universitaetsklinikum Freiburg; 🇩🇪 Freiburg, Germany

Centrum Medyczne Plejady; 🇵🇱 Krakow, Poland

Medycyna Kliniczna; 🇵🇱 Warsaw, Poland

Medical Center Harmoniya Krasy; 🇺🇦 Kyiv, Ukraine